Evaluation of Reduced-Dose Decitabine and Azacitidine for Treating Myelodysplastic Syndromes: A Retrospective Study

BACKGROUND: Hypomethylating agents (HMA) are considered the first-line therapy for high-risk myelodysplastic syndromes (MDS). However, as the efficacy and safety of rational dosing regimens are lacking, we evaluated the effectiveness and safety of reduced-dose azacitidine (AZA) vs. decitabine (DAC)...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Med Sci Monit
Prif Awduron: Hu, Naibo, Qin, Tiejun, Du, Xiaoyan, Wang, Bingyi, Wang, Xiaoyun, Xu, Zefeng, Pan, Lijuan, Qu, Shiqiang, Xiao, Zhijian
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: International Scientific Literature, Inc. 2021
Pynciau:
Clinical Research
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC7856837/
https://ncbi.nlm.nih.gov/pubmed/33514682
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12659/MSM.928454
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg